Christopher Jackson

Christopher Jackson – CEO & President

Mr. Jackson has over 32 years experience in healthcare sales & marketing, including 25 years of involvement with healthcare start-ups. Mr. Jackson has launched over 35 products during his career, with the majority in the field of women’s health & reproductive medicine.

1st Cystic Fibrosis Screening test 1989 Nichols Institute – San Juan Capistrano, CA
1st HIV Genotyping Test 1996 Specialty Laboratories – Santa Monica, CA
1st fFN Test for Preterm Labor 1999 Adeza Biomedical – Sunnyvale, CA
Beta 3 Integrin Test 1999 Adeza Biomedical – Sunnyvale, CA
AmniSure Test for PROM 2006 Amnisure, Inc – Boston, MA
PathCentral LIS Software 2010 PathCentral,Inc. - Irvine, CA
ClearpathDerm Digital Software 2016 DLCS – Dayton, OH

With experience in product management, healthcare marketing and building and managing successful sales teams, Mr. Jackson is excited about ReceptivaDxTM and the powerful information it provides for women with previously unexplained infertility.

Dr. Bruce Lessey

Bruce Lessey, M.D., Ph.D. – Scientific Advisor

Dr. Lessey is the Scientific Advisor for CiceroDx, Inc. and is an internationally recognized leader in uterine receptivity research and the identification of markers associated with unexplained infertility. Dr. Lessey’s extensive research background includes published research on Beta 3 Integrin and BCL6, the two key components of the current ReceptivaDxTM Assay. He has served on multiple editorial boards for major journals and published over 150 peer reviewed articles, with a focus on infertility, endometriosis and the role of the endometrium in embryo implantation.

In addition to his research efforts, Dr. Lessey is a practicing Ob-Gyn at The Fertility Center of the Carolinas in Greenville, SC. Dr. Lessey has been helping women overcome the challenges of infertility for over 3 decades, bringing the key findings of his research into the clinical setting and helping women conceive that had given up hope of ever becoming pregnant.

Board Certification:
American Board of Obstetrics and Gynecology with added qualifications in Reproductive Endocrinology and Infertility

Reproductive Endocrinology and Infertility, Hospital of the University of Pennsylvania

American College of Obstetricians and Gynecologists, American Society of Reproductive Medicine, American Association for the Advancement of Science

Endometriosis, integrins and uterine receptivity, and polycystic ovary disease

David Schammel, M.D. - Pathologist

Dr. David Schammel is the lead pathologist for all ReceptivaDxTM testing for CiceroDx, Inc. . Dr. Schammel, a partner of Pathology Associates in Greenville, SC, has been involved with uterine receptivity testing for over 10 years. Dr. Schammel currently serves as the Medical Director for Pathology Consultants, Inc and is based at the main campus of the Greenville Health System in Greenville, SC.

Board Certification:
Board certified in anatomic and Clinical Pathology

Medical School:
University of Minnesota School of Medicine

University of New Mexico

Surgical pathology fellowship - University of Minnesota

Previous Experience:
Vice Chairman of the Gynecologic and Breast Department of the AFIP in Washington, DC.
Subscribe to our newsletter and stay up to date with ReceptivaDx.
The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.
© 2017 Receptivadx. All Rights Reserved